Pitozinameran

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Nucleic Acid Created by `admin` on `Wed Apr 02 18:37:34 GMT 2025` Edited by `admin` on `Wed Apr 02 18:37:34 GMT 2025`
Nucleic Acid Type	mRNA VACCINE
Sequence Origin	VIRAL
Sequence Type	COMPLETE
Record UNII	8VLF8J3FR3
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

RNA (recombinant 5?-[1,2-[(3?-O-methyl)m7G-(5??5?)-ppp-Am]]-capped all uridine?N1-methylpseudouridine-substituted severe acute respiratory syndrome coronavirus 2 spike glycoprotein secretory signal peptide plus codon-optimized pre-fusion spike glycoprote

Preferred Name

English

Pitozinameran

Official Name

English

messenger RNA (mRNA), 5'-capped, encoding a full-length, codon-optimised pre-fusion stabilised conformation variant (K982P and V983P) of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) spike (S) glycoprotein (Omicron sub-lineage XBB.1.16

Common Name

English

pitozinameran [INN]

Common Name

English

Code System Code Type Description

NCI_THESAURUS

C203099

Created by admin on Wed Apr 02 18:37:34 GMT 2025 , Edited by admin on Wed Apr 02 18:37:34 GMT 2025

PRIMARY

SMS_ID

300000051269

Created by admin on Wed Apr 02 18:37:34 GMT 2025 , Edited by admin on Wed Apr 02 18:37:34 GMT 2025

PRIMARY

FDA UNII

8VLF8J3FR3

Created by admin on Wed Apr 02 18:37:34 GMT 2025 , Edited by admin on Wed Apr 02 18:37:34 GMT 2025

PRIMARY

INN

13089

Created by admin on Wed Apr 02 18:37:34 GMT 2025 , Edited by admin on Wed Apr 02 18:37:34 GMT 2025

PRIMARY

CAS

2920299-36-9

Created by admin on Wed Apr 02 18:37:34 GMT 2025 , Edited by admin on Wed Apr 02 18:37:34 GMT 2025

PRIMARY

Sugar	Site Range	Site Count
D-Ribose (RNA)	1_1-1_4271	4271 / 4271

Linkage	Site Range	Site Count
Phosphate	1_2-1_4271	4270 / 4270

Related Record Type Details


					B6L4N5Z4GH

SARS-COV2

TARGET ORGANISM->GENE MODIFIED PROTEIN

Amount:

Related Record Type Details


					8VLF8J3FR3

ACTIVE MOIETY

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
NUCLEOTIDE SUBSTITUTION	[1_1]	5'-TERMINUS			m2-7,3’-OGppp(m1-2’-O)Ap mRNA CAP	VNP8CZY34V
NUCLEOSIDE BASE SUBSTITUTION		RESIDUE_SPECIFIC	U		N1-METHYLPSEUDOURIDINE	09RAD4M6WF